OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Psychopharmacology is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
The dosing procedure that “makes the poison”: Comparing the effects of single versus cumulative alcohol administration methods on emotion recognition	262
Psychedelics and the ‘inner healer’: Myth or mechanism?	187
Which are the demographic and clinical characteristics of patients who respond to subcutaneous esketamine?	107
Science, safety and education: Informing the psychedelic treatment of psychiatric disorders	94
Off the RADAR; questions regarding the trial protocol of a randomised controlled trial of antipsychotic reduction and discontinuation	74
5-HT_1B receptor agonist attenuates cocaine self-administration after protracted abstinence and relapse in rats	71
Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study	65
Glutamate levels across deep brain structures in patients with a psychotic disorder and its relation to cognitive functioning	57
The chronic effects of a combination of herbal extracts (Euphytose^®) on psychological mood state and response to a laboratory stressor: A randomised, placebo-controlled, double blind study	56
Co-use of psychedelics with other substances: Findings from the global psychedelic survey	54
Relationship between depression, prefrontal creatine and grey matter volume	53
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat	52
Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice	51
The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies	49
Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study	47
Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a	44
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study	43
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy	43
An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine	41
Effects of 31 recombinant CYP2C19 variants on clomipramine metabolism in vitro	41
The Journal of Psychopharmacology: La Plus ça change. . .	40
Pharmaco-fUS in cognitive impairment: Lessons from a preclinical model	39
The D1/D2-like receptor antagonist flupentixol and the D2-like receptor antagonist L-741626 decrease operant responding for nicotine and food and locomotor activity in male and female rats	36
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool	36
Repurposing psychopharmacology: A two-way street?	36

Associations between regular cannabis use and brain resting-state functional connectivity in adolescents and adults	35
A framework for assessment of adverse events occurring in psychedelic-assisted therapies	34
Relationship between change in social evaluation learning and mood in early antidepressant treatment: A prospective cohort study in primary care	33
Not too quick on “Debunking the myth of ‘Blue Mondays’”	32
Ketamine use in a large global sample: Characteristics, patterns of use and emergency medical treatment	32
Voluntary nicotine consumption and reward in a subset of diversity outbred founder strains	32
The New Zealand drug harms ranking study: A multi-criteria decision analysis	31